Scholar Rock Holding Corporation · NASDAQ:SRRK

Scholar Rock — Q1 2026 Earnings Presentation

22 slides from Scholar Rock's earnings presentation, May 7, 2026

1. Slide 1: Q1 2026 Earnings Call

   © 2026 Scholar Rock, Inc. All rights reserved. Q1 2026 Earnings Call MAY 7, 2026 Exhibit 99.2

2. Slide 2: Q1 2026 Earnings Call agenda and speakers

   © 2026 Scholar Rock, Inc. All rights reserved. 2 TOPIC SPEAKER BUSINESS UPDATE David L. Hallal Chairman & Chief Executive Officer R&D PROGRESS Akshay Vaishnaw, M.D., Ph.D. President of R&D COMMERCIAL READINESS Keith Woods Chief Operating Officer COMPANY FINANCIALS Vikas Sinha Chief Financial Officer

3. Slide 3: Forward-Looking Statements

   © 2026 Scholar Rock, Inc. All rights reserved. 3 Forward-Looking Statements Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock Holding Corporation and Scholar Rock, Inc. (collectively, “Scholar Rock”), including without limitation, Scholar

4. Slide 4: Business Update

   © 2026 Scholar Rock, Inc. All rights reserved. Business Update David L. Hallal Chairman and Chief Executive Officer 4

5. Slide 5: Scholar Rock is positioned for a pivotal year ahead

   © 2026 Scholar Rock, Inc. All rights reserved. 5 Scholar Rock is positioned for a pivotal year ahead Our top priority: Bringing apitegromab to children and adults living with SMA BLA, Biologics License Application; PDUFA, Prescription Drug User Fee Act. Included in BLA resubmission, providing two in

6. Slide 6: Two independent paths to apitegromab FDA approval by September 30th PDUFA date

   © 2026 Scholar Rock, Inc. All rights reserved. 6 Two independent paths to apitegromab FDA approval by September 30th PDUFA date BLA, Biologics License Application; PDUFA, Prescription Drug User Fee Act. U.S. Commercial team is ready to launch apitegromab immediately upon FDA approval FDA Completes R

7. Slide 7: Scholar Rock is poised for a transformative year

   © 2026 Scholar Rock, Inc. All rights reserved. SHAPING THE FUTURE OF TREATMENT FOR PATIENTS LIVING WITH RARE NEUROMUSCULAR DISEASES INITIATE PHASE 2 STUDY for apitegromab in facioscapulohumeral muscular dystrophy SRK-439 PHASE 1 STUDY topline data in healthy volunteers MID - 2026 H2 2026 APITEGROMAB

8. Slide 8: R&D Progress

   © 2026 Scholar Rock, Inc. All rights reserved. R&D Progress Akshay Vaishnaw, M.D., Ph.D. President of R&D 8

9. Slide 9: Advancing Scholar Rock's world-leading anti-myostatin pipeline

   © 2026 Scholar Rock, Inc. All rights reserved. 9 Advancing Scholar Rock’s world-leading anti-myostatin pipeline *Following FDA and EMA regulatory approval of IV apitegromab; YoA, Years of Age; PDUFA, Prescription Drug User Fee Act; CHMP, Committee for Medicinal Products for Human Use. Program Indica

10. Slide 10: Phase 2 OPAL study of apitegromab in infants and toddlers with SMA

    © 2026 Scholar Rock, Inc. All rights reserved. Evaluating PK, PD, efficacy, safety, and tolerability of apitegromab over 48 weeks 1 0 Furthering our commitment to broad SMA community Ongoing Phase 2 OPAL study evaluating apitegromab in infants and toddlers with SMA PK, Pharmacokinetic; PD, Pharmacod

11. Slide 11: FSHD: Rare, devastating NMD with significant unmet need

    © 2026 Scholar Rock, Inc. All rights reserved. 1 1 FSHD: Rare, devastating NMD with significant unmet need >30,000 patients diagnosed in U.S. and Europe1-3; no approved therapies FLExD, FLExDUX4.Cre; FSHD, facioscapulohumeral muscular dystrophy; NMD, Neuromuscular Disease; WT, wild type; Ab, antibod

12. Slide 12: Advancing innovation with subcutaneous apitegromab and SRK-439

    © 2026 Scholar Rock, Inc. All rights reserved. 1 2 Advancing innovation with subcutaneous apitegromab and SRK-439 SRK-439 is a novel, investigational myostatin inhibitor. Leveraging world-leading expertise to drive continued innovation Subcutaneous Apitegromab Phase 1 study comparing intravenous (IV

13. Slide 13: Commercial Readiness

    © 2026 Scholar Rock, Inc. All rights reserved. Commercial Readiness Keith Woods Chief Operating Officer 1 3

14. Slide 14: Muscle strength and motor function remain the top unmet need in SMA

    © 2026 Scholar Rock, Inc. All rights reserved. 1 4 Muscle strength and motor function remain the top unmet need in children and adults living with SMA SMA, Spinal Muscular Atrophy. Scholar Rock’s disease education program continues to focus on a broader understanding of SMA as a disease of the motor

15. Slide 15: U.S. commercial team operating with urgency to prepare for launch

    © 2026 Scholar Rock, Inc. All rights reserved. 1 5 U.S commercial team operating with urgency to prepare for launch SMA, Spinal Muscular Atrophy. SMA Treatment Centers, SMA Prescribing Physicians, Multi-Disciplinary Care Teams TARGETING >2,600 SMA Prescribers TARGETING 140 SMA Centers Patient Engage

16. Slide 16: Strong momentum with apitegromab launch readiness in Europe

    © 2026 Scholar Rock, Inc. All rights reserved. 1 6 Strong momentum with apitegromab launch readiness in Europe in advance of mid-2026 CHMP opinion SMA, Spinal Muscular Atrophy; CHMP, Committee for Medicinal Products for Human Use. 1 Building world-class team 2 Engaging the SMA community 3 Establishi

17. Slide 17: ~35,000 SMA patients have received an approved SMN-targeted therapy

    © 2026 Scholar Rock, Inc. All rights reserved. ~35,000 SMA patients have received an approved SMN-targeted therapy1-3 Powering Scholar Rock through the end of this decade and into the next 1 7 Global apitegromab opportunity in SMA alone offers potential for many years of sustainable growth 1. Biogen

18. Slide 18: Company Financials

    © 2026 Scholar Rock, Inc. All rights reserved. Company Financials Vikas Sinha Chief Financial Officer 1 8

19. Slide 19: Operating with financial discipline to achieve our ambitions

    © 2026 Scholar Rock, Inc. All rights reserved. 1 9 Operating with financial discipline to achieve our ambitions as of March 31, 2026 $480M in cash and equivalents Prioritized investments focused on: Apitegromab commercial launch readiness in the U.S. and Europe 1 Strengthening supply chain to suppor

20. Slide 20: Closing Remarks

    © 2026 Scholar Rock, Inc. All rights reserved. Closing Remarks David L. Hallal Chairman and Chief Executive Officer 2 0

21. Slide 21: Q&A

    © 2026 Scholar Rock, Inc. All rights reserved. Q&A 2 1

22. Slide 22: For more information, please contact

    © 2026 Scholar Rock, Inc. All rights reserved. For more information, please contact: ir@scholarrock.com media@scholarrock.com Or visit us at www.scholarrock.com 2 2

Scholar Rock Holding — Q1 2026 Earnings Presentation on 6ix